Day One Biopharma surges on promising data for childhood brain cancer drug
13/06/2022 19:21
(Updates with milestone)
** Shares of Day One Biopharma DAWN.O more than double in
afternoon trade to $15.90, touching highest levels in over four
months
** Stock among top pct gainers on the Nasdaq
** DAWN reports 64% overall response rate for its drug
tovorafenib in pediatric low-grade glioma (plGG), the most
common type of childhood brain cancer, according to data from
the first 25 patients in a mid-stage trial urn:newsml:reuters.com:*:nGNX5PqLnX
** Co says the drug was generally well-tolerated
** Co is testing tovorafenib in patients aged 6 months to 25
years as a treatment for relapsed or progressive pLGG
** There are currently no approved treatments or standard of
care in the United States for pLGG
** DAWN expects to report top-line results from the full
trial population in Q1 2023
** Including Monday's session, DAWN down ~17% vs a 28%
decline in the Nasdaq Biotechnology Index .NBI YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))